DISCO Pharmaceuticals GmbH Revenue and Competitors

Cologne, DE

Location

$22M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • DISCO Pharmaceuticals GmbH's estimated annual revenue is currently $6.2M per year.(i)
  • DISCO Pharmaceuticals GmbH's estimated revenue per employee is $201,000
  • DISCO Pharmaceuticals GmbH's total funding is $22M.

Employee Data

  • DISCO Pharmaceuticals GmbH has 31 Employees.(i)
  • DISCO Pharmaceuticals GmbH grew their employee count by 7% last year.

DISCO Pharmaceuticals GmbH's People

NameTitleEmail/Phone
1
Chief Operating Officer (COO) and founderReveal Email/Phone
2
Chief Business OfficerReveal Email/Phone
3
Project LeaderReveal Email/Phone
4
Administration AssistantReveal Email/Phone
5
Research AssociateReveal Email/Phone
6
Research AssociateReveal Email/Phone
7
Project LeaderReveal Email/Phone
8
BTAReveal Email/Phone
9
Scientist and Project Lead - Cell Surface ProteomicsReveal Email/Phone
10
Executive AssistantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$52.5M26119%N/AN/A
#2
$17.3M8623%N/AN/A
#3
$3252.4M16181-2%N/AN/A
#4
$14.1M7030%N/AN/A
#5
$81.4M4058%$224MN/A
#6
$6.2M317%$22MN/A
#7
$12.3M6169%N/AN/A
Add Company

What Is DISCO Pharmaceuticals GmbH?

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.

keywords:N/A

$22M

Total Funding

31

Number of Employees

$6.2M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M31N/AN/A
#2
$5.3M3268%$3M
#3
$7.7M35-67%N/A
#4
$4M3633%N/A
#5
$4.6M38111%N/A